search
Back to results

Topiramate's Effects on Heavy Drinking (TOPMRI)

Primary Purpose

Alcohol Drinking

Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Topiramate
Placebo
Sponsored by
University of Pennsylvania
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alcohol Drinking

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Physically healthy, as determined by a comprehensive physical examination and approval of the study physician, males or females who drink alcohol, ages 18-60.
  • Average weekly ethanol consumption of >24 standard drinks for men, or >18 standard drinks for women.
  • Females must be non-pregnant, non-lactating and either be of non-childbearing potential (i.e. sterilized via hysterectomy or bilateral tubal ligation or at least 2 years postmenopausal) or of child bearing potential but practicing a medically acceptable method of birth control. Examples of medically acceptable methods for this protocol include: the birth control pill, intrauterine device, injection of Depo-Provera, Norplant, contraceptive patch, contraceptive ring, double-barrier methods (such as condoms and diaphragm/spermicide), male partner sterilization, abstinence (and agreement to continue abstinence or to use an acceptable method of contraception, as listed above, should sexual activity commence), and tubal ligation.
  • Provide voluntary informed consent.
  • Must be able to read. [Subjects are required to be able to read because there are several self-administered measures that they must read, understand and provide written answers.]
  • Intelligence quotient of ≥ 80.

Exclusion Criteria:

  • Current, clinically significant physical disease or abnormality on the basis of medical history, physical examination, or routine laboratory evaluation.
  • History of head trauma or injury causing loss of consciousness, lasting more than five (5) minutes or associated with skull fracture or inter-cranial bleeding or abnormal MRI.
  • Current major DSM-IV Axis I diagnoses other than alcohol use disorder (except nicotine use disorder).
  • Presence of magnetically active irremovable prosthetics, plates, pins, permanent retainer, bullets, etc. (unless a radiologist confirms that it's presence is unproblematic). An x-ray may be obtained to determine eligibility given the possibility of a foreign body.
  • History of a serious psychiatric illness including psychosis, bipolar disorder, or suicidal or homicidal intent.
  • Current treatment with carbonic anhydrase inhibitors.
  • Claustrophobia or other medical condition preventing subject from lying in the MRI for approximately one (1) hour.
  • Current regular treatment with psychotropic medications (e.g., benzodiazepines, antidepressants), which affect neurotransmitter systems or a medication being used to treat alcohol use disorders (e.g., naltrexone, acamprosate).
  • Vision problems that cannot be corrected with glasses.
  • Body Mass Index (BMI) greater than or equal to 34, body girth greater than 52 inches and a head girth greater than 25 inches.
  • History of stroke and/or stroke related spasticity.
  • History of glaucoma or kidney stones.
  • HIV positive.
  • History of seizures.
  • History of topiramate treatment for alcohol use disorder and report no treatment response.
  • Current DSM-5 diagnosis of alcohol use disorder that is clinically too severe to permit them to participate in a research trial in which the goal is to stop or reduce drinking.

Sites / Locations

  • University of Pennsylvania Center for Studies of Addiction

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Topiramate

Placebo

Arm Description

up to 200mg/day orally (over 8 weeks during which the dosage is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)

placebo

Outcomes

Primary Outcome Measures

fMRI Response in the Ventral Striatum/Medial Orbitofrontal Cortex During Alcohol Cue Exposure
At baseline (prior to randomization), brain and behavioral responses will be significantly greater during alcohol cue exposure compared to non-alcohol cue exposure. Following 6 weeks of study drug, individuals receiving topiramate will demonstrate greater reductions in brain activity and drinking behavior compared to individuals receiving placebo. Individuals receiving placebo will exhibit responses similar to baseline responses.

Secondary Outcome Measures

Drinking Days
change in drinking days from baseline to 9 weeks
Change in Gamma-glutamyl Transferase (GGT) or Carbohydrate-deficient Transferrin (CDT) Levels
Change in gamma-glutamyl transferase (GGT) or carbohydrate-deficient transferrin (CDT) levels after 9 weeks of treatment.
Heavy Drinking Days
change in number of heavy drinking days from baseline to 9 weeks
Mean Alcohol Consumption
change in mean alcohol consumption from baseline to 9 weeks

Full Information

First Posted
February 20, 2014
Last Updated
August 20, 2018
Sponsor
University of Pennsylvania
search

1. Study Identification

Unique Protocol Identification Number
NCT02074904
Brief Title
Topiramate's Effects on Heavy Drinking
Acronym
TOPMRI
Official Title
Brain Mechanisms of Topiramate's Effects on Heavy Drinking
Study Type
Interventional

2. Study Status

Record Verification Date
December 2017
Overall Recruitment Status
Terminated
Why Stopped
We terminated the study to run it as a sub-study of NCT02371889, which is a 13 week, placebo controlled, double-blind, trial of topiramate in heavy drinkers.
Study Start Date
May 2015 (undefined)
Primary Completion Date
March 2017 (Actual)
Study Completion Date
March 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Pennsylvania

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The proposed project will utilize perfusion functional magnetic resonance imaging (fMRI) to examine the effects of topiramate on brain and behavioral responses in heavy drinkers to appetitive alcohol reminders (cues that motivate continued alcohol use and relapse). This project will yield novel findings on brain and behavioral responses to alcohol cues, the effects of topiramate on alcohol cue reactivity, and the mechanisms underlying topiramate's ability to blunt alcohol cue reactivity and heavy drinking.
Detailed Description
This project is a double-blind, randomized, placebo-controlled study of topiramate's effects on brain and behavior responses in heavy drinkers. Eligible volunteers who meet study criteria will be randomized to receive either topiramate or placebo with weekly visits and medication management sessions. Participants will complete two magnetic resonance imaging sessions. The first scan session will occur prior to starting study drug, and the second scan will occur following six weeks of study drug. This project will yield novel findings on brain and behavioral responses to alcohol cues, the effects of topiramate on alcohol cue reactivity, and the mechanisms underlying topiramate's ability to blunt alcohol cue reactivity and heavy drinking.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alcohol Drinking

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
1 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Topiramate
Arm Type
Experimental
Arm Description
up to 200mg/day orally (over 8 weeks during which the dosage is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
placebo
Intervention Type
Drug
Intervention Name(s)
Topiramate
Other Intervention Name(s)
Topamax
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
fMRI Response in the Ventral Striatum/Medial Orbitofrontal Cortex During Alcohol Cue Exposure
Description
At baseline (prior to randomization), brain and behavioral responses will be significantly greater during alcohol cue exposure compared to non-alcohol cue exposure. Following 6 weeks of study drug, individuals receiving topiramate will demonstrate greater reductions in brain activity and drinking behavior compared to individuals receiving placebo. Individuals receiving placebo will exhibit responses similar to baseline responses.
Time Frame
baseline to after 6 weeks of study drug
Secondary Outcome Measure Information:
Title
Drinking Days
Description
change in drinking days from baseline to 9 weeks
Time Frame
baseline and 9 weeks
Title
Change in Gamma-glutamyl Transferase (GGT) or Carbohydrate-deficient Transferrin (CDT) Levels
Description
Change in gamma-glutamyl transferase (GGT) or carbohydrate-deficient transferrin (CDT) levels after 9 weeks of treatment.
Time Frame
baseline and Visit 9 (9 weeks)
Title
Heavy Drinking Days
Description
change in number of heavy drinking days from baseline to 9 weeks
Time Frame
baseline to 9 weeks
Title
Mean Alcohol Consumption
Description
change in mean alcohol consumption from baseline to 9 weeks
Time Frame
baseline to 9 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Physically healthy, as determined by a comprehensive physical examination and approval of the study physician, males or females who drink alcohol, ages 18-60. Average weekly ethanol consumption of >24 standard drinks for men, or >18 standard drinks for women. Females must be non-pregnant, non-lactating and either be of non-childbearing potential (i.e. sterilized via hysterectomy or bilateral tubal ligation or at least 2 years postmenopausal) or of child bearing potential but practicing a medically acceptable method of birth control. Examples of medically acceptable methods for this protocol include: the birth control pill, intrauterine device, injection of Depo-Provera, Norplant, contraceptive patch, contraceptive ring, double-barrier methods (such as condoms and diaphragm/spermicide), male partner sterilization, abstinence (and agreement to continue abstinence or to use an acceptable method of contraception, as listed above, should sexual activity commence), and tubal ligation. Provide voluntary informed consent. Must be able to read. [Subjects are required to be able to read because there are several self-administered measures that they must read, understand and provide written answers.] Intelligence quotient of ≥ 80. Exclusion Criteria: Current, clinically significant physical disease or abnormality on the basis of medical history, physical examination, or routine laboratory evaluation. History of head trauma or injury causing loss of consciousness, lasting more than five (5) minutes or associated with skull fracture or inter-cranial bleeding or abnormal MRI. Current major DSM-IV Axis I diagnoses other than alcohol use disorder (except nicotine use disorder). Presence of magnetically active irremovable prosthetics, plates, pins, permanent retainer, bullets, etc. (unless a radiologist confirms that it's presence is unproblematic). An x-ray may be obtained to determine eligibility given the possibility of a foreign body. History of a serious psychiatric illness including psychosis, bipolar disorder, or suicidal or homicidal intent. Current treatment with carbonic anhydrase inhibitors. Claustrophobia or other medical condition preventing subject from lying in the MRI for approximately one (1) hour. Current regular treatment with psychotropic medications (e.g., benzodiazepines, antidepressants), which affect neurotransmitter systems or a medication being used to treat alcohol use disorders (e.g., naltrexone, acamprosate). Vision problems that cannot be corrected with glasses. Body Mass Index (BMI) greater than or equal to 34, body girth greater than 52 inches and a head girth greater than 25 inches. History of stroke and/or stroke related spasticity. History of glaucoma or kidney stones. HIV positive. History of seizures. History of topiramate treatment for alcohol use disorder and report no treatment response. Current DSM-5 diagnosis of alcohol use disorder that is clinically too severe to permit them to participate in a research trial in which the goal is to stop or reduce drinking.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Reagan R Wetherill, PhD
Organizational Affiliation
University of Pennsylvania
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Henry R Kranzler, MD
Organizational Affiliation
University of Pennsylvania
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Pennsylvania Center for Studies of Addiction
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Topiramate's Effects on Heavy Drinking

We'll reach out to this number within 24 hrs